<DOC>
	<DOC>NCT00949533</DOC>
	<brief_summary>This open-label randomized 2 arm study will determine the emergence of viral resistance in participants with seasonal influenza A infection treated with oseltamivir. Eligible participants less than or equal to (&lt;/=) 5 years of age will be randomized to receive oseltamivir at either standard dose (30-75 milligrams [mg] orally twice daily [bid]) or double dose (60-150 mg orally bid) for 5 days. Target sample size is greater than (&gt;) 100.</brief_summary>
	<brief_title>A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>positive rapid antigen test for influenza A onset of symptoms of influenza (fever, at least one respiratory symptom) &lt;/=48 hours clinical suspicion of infection with a respiratory virus other than influenza suspicion of invasive bacterial infection evidence of poorly controlled underlying disease known immunosuppression known allergy to Oseltamivir women who are pregnant or planning to get pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>